Genmab — April 2021

[E_L]

or could be, depends on data offcourse

[E_L]

Teclistamab and talquetamab modulate levels of soluble B-cell maturation antigen in patients with relapsed and/or refractory multiple myeloma.

[E_L]

Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).

[E_L]

Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).

[Bulder]

I assume that only the first epco abs will contain data. The second one looks more like a presenting abs.

[E_L]

makes sense

[E_L]

1 Tiso - Tisotumab vedotin versus investigator’s choice chemotherapy in second- or third-line recurrent or metastatic cervical cancer (innovaTV 301/ENGOT‑cx12/GOG 3057, trial in progress).

[Bulder]

The new guy from Vejle is primary author on the firste epco-abs. Will be interesting how new dara are.

[E_L]

13x Dara; i would think the 2 most interesting are on Auriga and Cassiopeia 'part 2' ?

[Bulder]

Hope we'll get the full expansion cohorte.

[Bulder]

That should provide us with data enough to judge on the future of epco.

[E_L]

so that's the abstract that will determine how our summer will be

[E_L]

A phase 1b, open-label, dose-escalation study to evaluate camidanlumab tesirine (Cami) as monotherapy in patients (pts) with advanced solid tumors.

[Bulder]

strange that we don't hear anything from the Cepheus study. It had primary completion earlier this month.

[E_L]

do you think it could be important enough for a late breaker?

[Bulder]

could be

[Sukkeralf]

Or EHA - one of them
would be nice

[GeorgeBest]

https://meetinglibrary.asco.org/results/Glofitamab ?filters=JTVCJTdCJTIyZmllbGQlMjIlM0ElMjJZZWFyJTIyJTJDJTIydmFsdWUlMjIlM0ElMjIyMDIxJTIyJTJDJTIycXVlcnlWYWx1ZSUyMiUzQSUyMjIwMjElMjIlMkMlMjJjaGlsZHJlbiUyMiUzQSU1QiU1RCU3RCU1RA%3D%3D&page=1
Glofitamab har 2 abstracts

[GeorgeBest]

https://meetinglibrary.asco.org/results/Mosunetuzumab ?filters=JTVCJTdCJTIyZmllbGQlMjIlM0ElMjJZZWFyJTIyJTJDJTIydmFsdWUlMjIlM0ElMjIyMDIxJTIyJTJDJTIycXVlcnlWYWx1ZSUyMiUzQSUyMjIwMjElMjIlMkMlMjJjaGlsZHJlbiUyMiUzQSU1QiU1RCU3RCU1RA%3D%3D&page=1 Mosunetuzumab 1 abstract

[Doublo]

Tak Concillado for din kommentar jeg først ser nu, du har selvfølgelig ret, jeg tænkte bare om der var noget man særligt kunne være i tvivl om, p.t.
jeg mener der er indregnet risikoen for at voldgiften ikke bliver til GEN fordel, men det glemmer aktionærerne nok i første omgang! jeg har realiseret en del nu, men har været med siden 2015, og tror fuldt og fast på firmaet.